Clinical trials: Neoplasm, Uterine
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Uterine Fibroids (MeSH Heading: Leiomyoma)
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Multi-center, randomized, double-blind, parallel-group study to confirm non-inferiority of KLH-2109 to Leuprorelin acetate in uterine fibroids patient with menorrhagia
- Trial name
- NCT05440383
- Testing
- KLH-2109, Leuprorelin
- Where
- Japan
- Volunteers
- 287 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Menorrhagia, Uterine Fibroids
Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding
The objective of this study is to evaluate the safety and effectiveness of Doppler guided uterine artery occlusion (D-UAO) for the reduction of fibroid associated bleeding.
- Trial name
- DUAO (NCT00496080)
- Testing
- Doppler-Guided Uterine Artery Occlusion Device (DUAO)
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Ethicon, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Solid Tumors (Phase 1), HNSCC
MTX-531-001 Phase 1 Study in Advanced Solid Tumors
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors.
- Conditions
- Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer
- Trial name
- NCT07874880
- Testing
- MTX-531
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- MEKanistic Therapeutics, Inc.
Cervical Cancer
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
This study is a multi-center, prospective, open-label, single-arm phase II clinical study to evaluate the efficacy, safety and immunogenicity of GB226 in treatment of recurrent or metastatic cervical cancer patients with PD-L1…
- Trial name
- NCT03808857
- Testing
- GB226
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Genor Biopharma Co., Ltd.
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Vaginal Fluid Collection for Detection of Endometrial Cancer
The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia…
- Trial name
- NCT06294886
- Testing
- Screening test to detect endometrial cancer and precancer
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Innovis LLC
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
- Trial name
- NCT06897527
- Testing
- Dostarlimab
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer, Biliary Tract Cancer
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
In DESTINY-Pan-Tumor [DP-02], DESTINY CRC02 [DC-02], and DESTINY-Lung01 [DL-01], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients.
- Conditions
- Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06973161
- Where
- 27 sites in United States, Austria and 10 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT06034860
- Testing
- MT-8421, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Templates, Inc.
Advanced Solid Tumors, Breast Cancer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with…
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
- Trial name
- NCT07038369
- Testing
- ATV-1601, ATV-1601 + Fulvestrant
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 134 people
- Sponsor
- Atavistik Bio, Inc
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or…
- Conditions
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
- Trial name
- NCT06547840
- Testing
- MOv18 IgE
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Epsilogen Ltd
Uterine Fibroids
Post Market Evaluation of Acessa With TAG
The purpose of this study is to test both user preference and speed of targeting with the use of the Acessa System with Targeting Animation Guidance (TAG).
- Trial name
- TAG (NCT01842789)
- Testing
- Acessa Procedure
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Acessa Health, Inc.
Uterine Fibroids
Safety Study of ExAblate for the Treatment of Uterine Fibroids
The objective of this Phase IV study is to evaluate the safety of the ExAblate treatment of uterine fibroids using the enhanced sonication techniques, based on the current commercially-approved treatment guidelines.
- Trial name
- NCT01142791
- Testing
- ExAblate
- Where
- 8 sites in United States
- Volunteers
- 121 people
- Sponsor
- InSightec
Esophageal Cancer, Gastric Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
- Conditions
- Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
- Trial name
- NCT05438420
- Testing
- Q702, Pembrolizumab
- Where
- 7 sites in United States, South Korea
- Volunteers
- 120 people
- Sponsor
- Qurient Co., Ltd.
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Neoplasms, Endometrial
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care.
- Trial name
- NCT07286331
- Testing
- Mocertatug rezetecan, Paclitaxel, Doxorubicin
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline